1/2
A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble
Read More
AstraZeneca (AZN.L) will move finance chief Marc Dunoyer to head newly acquired rare diseases business Alexion (ALXN.O), using the $39 billion takeover as an opportunity to freshen up a management team that had been in place for eight years.
Chief Executive Pascal Soriot has faced heavy public criticism and EU legal action after AstraZeneca missed targets for coronavirus vaccine deliveries, with he and Dunoyer also attracting investor anger over their pay packages last month. read more
Dunoyer will replace Ludwig Hantson as boss of United States-based Alexion on completion of the agreed deal, with the proposed switch allowing Aradhana Sarin to move in the opposite direction and become AstraZeneca chief financial officer.